Neurocrine Biosciences Inc. (NASDAQ:NBIX) has been assigned a consensus recommendation of “Buy” from the eleven analysts that are covering the company. One research analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $64.00.

NBIX has been the topic of a number of analyst reports. Robert W. Baird restated an “outperform” rating and issued a $66.00 price objective on shares of Neurocrine Biosciences in a research report on Tuesday, August 30th. HC Wainwright restated a “buy” rating on shares of Neurocrine Biosciences in a research report on Friday, August 5th. Leerink Swann initiated coverage on shares of Neurocrine Biosciences in a research report on Tuesday. They issued an “outperform” rating and a $70.00 price objective on the stock. Jefferies Group restated a “buy” rating on shares of Neurocrine Biosciences in a research report on Wednesday, June 8th. Finally, TheStreet cut shares of Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, July 14th.

Neurocrine Biosciences (NASDAQ:NBIX) opened at 51.26 on Monday. The firm’s market capitalization is $4.45 billion. Neurocrine Biosciences has a 12 month low of $31.25 and a 12 month high of $58.46. The firm’s 50-day moving average is $50.99 and its 200 day moving average is $47.34.

In other news, Director Corinne H. Nevinny sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $48.54, for a total value of $242,700.00. Following the transaction, the director now owns 25,555 shares in the company, valued at $1,240,439.70. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Christopher Flint Obrien sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $48.73, for a total transaction of $609,125.00. Following the completion of the transaction, the insider now owns 55,044 shares in the company, valued at approximately $2,682,294.12. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC increased its position in shares of Neurocrine Biosciences by 5.1% in the first quarter. Geode Capital Management LLC now owns 582,969 shares of the company’s stock valued at $23,056,000 after buying an additional 28,169 shares in the last quarter. Pictet Asset Management Ltd. increased its position in shares of Neurocrine Biosciences by 26.6% in the first quarter. Pictet Asset Management Ltd. now owns 192,057 shares of the company’s stock valued at $7,064,000 after buying an additional 40,303 shares in the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Neurocrine Biosciences by 2.7% in the first quarter. UBS Asset Management Americas Inc. now owns 628,260 shares of the company’s stock valued at $24,847,000 after buying an additional 16,498 shares in the last quarter. State Street Corp increased its position in shares of Neurocrine Biosciences by 22.9% in the first quarter. State Street Corp now owns 2,682,064 shares of the company’s stock valued at $106,077,000 after buying an additional 499,687 shares in the last quarter. Finally, Wexford Capital LP purchased a new position in shares of Neurocrine Biosciences during the first quarter valued at about $1,069,000. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

5 Day Chart for NASDAQ:NBIX

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.